Epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from Epithalamin, a thymus-and-pineal extract first isolated by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in the early 1980s. Epithalamin is the crude extract; Epitalon is the four-amino-acid sequence Khavinson's group pulled out as the biologically active core. The Khavinson protocol research is one of the longest-running single-peptide programmes in published gerontology, and it's almost entirely Russian literature.
Key Takeaways
- —Epitalon is a 4-amino-acid synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from natural Epithalamin, developed by the Khavinson Institute in St. Petersburg.
- —A 15-year cohort study in older adults (Khavinson et al., 2003) showed a 1.6–1.8× reduction in mortality in those receiving Epithalamin or Epitalon treatment cycles versus untreated controls.
- —Epitalon activates telomerase (hTERT expression) in somatic cells — extending telomere length in cultured human fetal fibroblasts across up to 44 additional population doublings (Khavinson et al., Bull Exp Biol Med, 2003).
- —Current regulatory status: not FDA-approved; available as research-grade peptide and, in some countries, as a compounded formulation.
Epitalon is the short synthetic version of Epithalamin, a bioregulator fraction the pineal gland and thymus produce naturally (Khavinson & Morozov, Neuroendocrinol Lett, 2003). Khavinson's core hypothesis, built over decades of bench and clinical work, is that the pineal puts out short peptides that regulate aging-related gene expression, and that dosing those peptides exogenously can partially restore a younger transcriptional profile in old tissue.
The tetrapeptide sequence Ala-Glu-Asp-Gly is the minimal active unit (Khavinson et al., Bull Exp Biol Med, 2002). It's water-soluble, small enough to penetrate tissue directly, and stable under standard peptide storage. Molecular weight sits around 390 Da, which makes it one of the smallest bioactive peptides anyone is actively researching.
The "peptide bioregulation" theory Khavinson built is genuinely different from conventional pharmacology. Instead of hitting a single receptor, Epitalon looks like a transcriptional regulator. It binds chromatin directly and modulates gene expression at the epigenetic level. That's not a receptor-agonist model. Published chromatin interaction data from the Khavinson group shows Epitalon interacting directly with promoter regions for antioxidant enzymes, melatonin synthesis genes, and telomerase reverse transcriptase.
Three mechanisms have the strongest published evidence base:
Telomerase activation (hTERT upregulation): the headline finding. Khavinson et al., Bull Exp Biol Med, 2003 showed Epitalon increased telomerase activity and hTERT expression in cultured human fetal fibroblasts. The cell line ran 44 additional population doublings past the Hayflick limit versus untreated controls. Telomere length held steady, and in some conditions extended.
Melatonin regulation: Epitalon increases melatonin synthesis and secretion from the pineal, particularly in aged animals where pineal output has dropped off (Anisimov et al., Neuroendocrinol Lett, 2003). That matters for circadian entrainment and for melatonin's downstream antioxidant and anti-inflammatory effects.
Antioxidant enzyme expression: consistent data across rat, mouse, and in-vitro models shows Epitalon upregulating SOD, catalase, and glutathione peroxidase (Anisimov et al., Mech Ageing Dev, 2003). Oxidative damage markers (lipid peroxidation, protein carbonylation) drop in treated animals, alongside modest lifespan extension in mice (Khavinson et al., Biogerontology, 2003).
Epitalon (Ala-Glu-Asp-Gly) increased telomerase activity and extended the replicative lifespan of human fetal fibroblasts by up to 44 additional population doublings beyond Hayflick's limit in published cell culture experiments (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2003). The mechanism involves upregulation of hTERT — the catalytic subunit of telomerase — at the transcriptional level, making Epitalon one of only a handful of compounds with published telomerase-activating data in human cells.
The most-cited clinical data comes from a 15-year longitudinal cohort run at the Geriatric Centre in St. Petersburg (Khavinson & Morozov, Neuroendocrinol Lett, 2003). Patients aged 60–74 got either Epithalamin peptide extract, Thymalin (another thymic peptide), or no treatment, with 15 years of follow-up. Sleep-consolidation and circadian improvements showed up later in older adults with pineal dysfunction (Korkushko et al., Bull Exp Biol Med, 2007). Key findings:
The limitation is real and worth saying out loud: these were not randomised controlled trials in the Western regulatory sense. Allocation wasn't randomised, and confounders weren't fully controlled. The Khavinson group's work has been published mostly in Russian journals and PMC translations, with limited independent replication by Western groups. Be honest about that when you're weighing the evidence.
The 48% vs 72% survival gap over 15 years is striking taken at face value. The caveat is the design: observational cohort, not a randomised trial. No independent prospective RCT replication has been published. Read the data as hypothesis-generating, not confirmatory. This is telomere play with one good cell-culture paper and one long Russian cohort behind it.
Published clinical protocols and the compounding literature land on the same framework:
| Parameter | Range | Notes |
|---|---|---|
| Dose per injection | 5–10 mg | Khavinson clinical protocols used 10 mg/day |
| Route | Subcutaneous or intramuscular | Both routes used in published work |
| Cycle duration | 10–20 days | Most commonly 10 days |
| Frequency | 1–2 cycles per year | Some longevity protocols use spring and autumn cycles |
| Reconstitution | Bacteriostatic water | Standard 1–2 mL per 10 mg vial |
Example cycle: 10 mg subq pin daily for 10 days, repeated once or twice per year. The classic Khavinson protocol is essentially "10 days on, then off until the next cycle." Some people run 5 mg for the first cycle to feel out tolerability before going up.
The Khavinson group typically used IM in their published work, but subq pinning is more practical and bioavailability is comparable for a peptide this small. Reco with BAC water, 1–2 mL per 10 mg vial, store cold once mixed.
Across every published Khavinson study and the wider animal literature, no serious adverse events have been attributed to Epitalon or Epithalamin. The compounds look well-tolerated at clinical doses in animals and human cohorts. Injection site reactions (transient local erythema) are the most commonly noted event. Anecdotally from the longevity crowd, the most reported subjective effects are sleep depth and HRV bumps, subjective but real for the people tracking it.
In Khavinson's published clinical work spanning over two decades and multiple cohort studies, neither Epitalon (tetrapeptide) nor its parent compound Epithalamin have been associated with serious adverse events. The safety data should be contextualised: trials were conducted primarily in St. Petersburg under protocols not fully equivalent to Western GCP standards, and independent third-party safety surveillance data is limited.
The lack of a randomised controlled trial under Western regulatory conditions means Epitalon doesn't carry the safety database FDA-reviewed compounds do. That's a real evidence gap, not evidence of safety. Anyone running Epitalon protocols is treating themselves as the lab rat, and the existing literature is preliminary until somebody independently replicates it. Could be placebo, but the cell-culture data is hard to wave off.
Before sourcing Epitalon, the Next Pep peptide library gives you the full profile: Ala-Glu-Asp-Gly tetrapeptide structure, telomerase/hTERT activation mechanism, the Khavinson cohort data, and the missing Western RCT validation, all cross-referenced against the published literature. That context matters when you're reading vendor copy that wildly oversells what the evidence actually shows.
Use the comparison tool to put Epitalon next to other longevity-focused peptides and look at mechanisms, evidence quality, and access routes side by side. If you're running any injectable, the dosing calculator handles reco maths: vial mg to draw volume and syringe units.
No. Epithalamin is a crude polypeptide extract isolated from the pineal gland and thymus. Epitalon (Ala-Glu-Asp-Gly) is the purified synthetic tetrapeptide that Khavinson's group identified as the active core sequence inside Epithalamin. Epitalon is more reproducible, easier to synthesise, and is the compound used in most modern research protocols. Older Khavinson studies used Epithalamin; newer work uses Epitalon.
Published cell culture data from Khavinson et al. (2003) shows Epitalon increased telomerase activity and let human fetal fibroblasts divide roughly 44 more times than untreated controls before hitting replicative senescence. That isn't the same as showing telomere lengthening in vivo in a healthy adult human. Those data don't exist yet. The cell-culture findings are real, but don't extrapolate them past what they are.
Most published Khavinson protocols use 10 days on with 5–10 mg daily, repeated 1–2 times per year (usually spring and autumn). The reasoning behind spacing cycles is to allow natural regulatory reset and avoid receptor desensitisation, though there's no formal receptor-downregulation data specific to Epitalon to anchor that.
Some people use intranasal Epitalon, but the published clinical and preclinical data is almost entirely subq or IM. Intranasal bioavailability data for Epitalon specifically hasn't been published. Given the size (390 Da), nasal absorption is plausible but unquantified. N=1 territory if you go that route.
The mechanisms are different. GHK-Cu is an endogenous tripeptide that modulates copper-dependent enzymes, MMP activity, and collagen synthesis. Its primary effects are on connective tissue remodelling and tissue-repair gene expression. Epitalon's primary action is at the telomerase/chromatin level with documented pineal–melatonin axis effects. Both are "epigenetic modulators" in a broad sense, but they target different biology, which is why people often run them together. The mechanisms don't overlap.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.